IL1B and recessive dystrophic epidermolysis bullosa: At the same time, it has been shown that MSCs can be used both intradermally and systemically, which is especially important in the case of RDEB patients who not only have skin lesions, but also systemic inflammatory diseases [29,30,93], whose pathogenesis is accompanied by proinflammatory cytokine IL-1β constantly produced by Ks that play an essential role [94,95].